Skip to main content
OpenTrials
Completed

NCT Number: NCT00962949

The Renin-Aldosterone Axis in Postural Tachycardia Syndrome

The purpose of this study is to determine the role of the renin-angiotensin-aldosterone in the pathophysiology of postural tachycardia syndrome, and to provide an insight about the disease process in this disorder.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Postural Orthostatic Tachycardia Syndrome (POTS) Autonomic Nervous System Diseases Nervous System Diseases Neurologic Manifestations Orthostatic Intolerance Pathological Conditions, Signs and Symptoms Postural Orthostatic Tachycardia Syndrome Primary Dysautonomias Signs and Symptoms

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Vanderbilt University

Nashville, Tennessee, 37232, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center criteria
  • Age between 18-64 years
  • Male or females are eligible
  • Able and willing to provide informed consent
  • Healthy control subjects with no major medical problem (including postural tachycardia syndrome), free of medications during the study

Exclusion criteria

  • Overt cause of postural tachycardia e.g., dehydration
  • Inability to give or withdraw informed consent
  • Pregnancy
  • Hypertension (BP > 140/90)
  • Significant co-morbid condition
  • Other factors which in the investigator's opinion would prevent the subject from completing the protocol

Treatment and study plan

Angiotensin II

Drug

Angiotensin II infusion for 1 hour

Primary outcomes

  1. Mean Arterial Blood Pressure Change

    Time frame: 1 hour

    Change in MAP from baseline to after 1h of infusion.

Secondary outcomes

  1. Plasma Renin Activity

    Time frame: 1 hour

    Change in plasma renin activity from baseline to after 1h of infusion.

  2. Aldosterone Level

    Time frame: 1 hour

    Change in aldosterone blood level from baseline to after 1h of infusion.

  3. Cortisol Level

    Time frame: 1 hour

    Change in cortisol blood level from baseline to after 1h of infusion.

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Registry information

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Aug 20, 2009
Registry last updated
Sep 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.